IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

	ation of: Tomas Ciniar				
Serial No.:	10/086,816	Group No.:	1632		
Filed:	February 28, 2002	Examiner:	Shin Lin Chen		
For:	NOVEL GENE ENCODING ORGANIC ANION TRANSPORTER				
P.O. Box 14	Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450				
TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT WITHIN THREE MONTHS OF FILING OR BEFORE MAILING OF FIRST OFFICE ACTION (37 CFR 1.97 (b))					
	CERTIFICATE OF MAILING				
	CE	RTIFICATE OF	MAILING		
deposited on	ify that this paper (along with a	any paper referr e United States	ed to as being attached or enclosed) is being Postal Service in an envelope addressed to the		
deposited on	ify that this paper (along with a the date shown below with the er for Patents, P.O. Box 1450,	any paper referr e United States Alexandria, VA	ed to as being attached or enclosed) is being Postal Service in an envelope addressed to the		
deposited on Commission	ify that this paper (along with a the date shown below with the er for Patents, P.O. Box 1450, (check and 37 CFR 1.8 (a) cient postage as	any paper referr e United States Alexandria, VA	ed to as being attached or enclosed) is being Postal Service in an envelope addressed to the 22313-1450.		

IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING INFORMATION DISCLOSURE STATEMENT

The information disclosure statement submitted herewith is being filed within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97 (b).

Reg. No. 35,071

Tel. No.: (650) 522-5569

SIGNATURE OF ATTORNEY

Mark L. Bosse

Type or print name of attorney

Gilead Sciences, Inc. 333 Lakeside Drive

P.O. Address

Foster City, CA 94404

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Tomas Cihlar

Serial No.: 10/086,816

Group No.: 1632

Filed:

February 28, 2002

Examiner: Shin Lin Chen

For:

NOVEL GENE ENCODING ORGANIC ANION TRANSPORTER

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT (modified)

List of Sections Forming Part of This Information Disclosure Statement.

The following sections are being submitted for this Information Disclosure Statement:

- 1. x Preliminary Statements
- 2. X FORM PTO 1449 (Modified)

Systember 26, 2003

3. x Copies of Listed Information Items Accompanying This Statement

Section 1. Preliminary statements

Applicants submit herewith patents, publications or other information of which they are aware, which they believe may be material to the examination of this application and in respect of which there may be a duty to disclose.

The filing of this information disclosure statement shall not be construed as a representation that a search has been made (37 CFR 1.97 (g)), an admission that the information cited is, or is considered to be, material to patentability or that no other material information exists.

The filing of this information disclosure statement shall not be construed as an admission against interest in any manner. Notice of January 9, 1992, 1135 O.G. 13-25, at 25.

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Robin Torres

(Type or print name of person mailing paper)

Dato.

(Signatur of pers n mailing paper)

		, , , , , , , , ,
U.S. DEPARTMENT OF COMMERCE	ATTY DOCKET NO.: 240.1PCD SERIAL NO.: 10/086,	
PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT	APPLICANT: Tomas Cihlar	
BY APPLICANT (37 CFR 1.98(b))	FILING DATE: 2/28/02	GROUP ART UNIT: 1632

U.S. PATENT DOCUMENTS

	EXAMR'S INITIALS	PATENT NO.	ISSUE DATE	PATENTEE	CLASS/ SUBCLASS	FILING DATE
ŀ						

FOREIGN PATENT DOCUMENTS

EXAMR'S INITIALS	PATENT NO.	PUBLICATION DATE	COUNTRY	CLASS/ SUBCLASS	TRANSLATION YES/NO
	WO 97/31111	8/28/97	PCT		
	WO 97/42321	11/13/97	PCT		
	WO 98/53064	11/26/98	PCT		yes

OTHER DOCUMENTS

EXAMR'S INITIALS	ARTICLE
	Apiwattanakul et al., "Transport Properties of Nonsteroidal Anti-Inflammatory Drugs by Organic Anion Transporter 1 Expressed in Xenopus laevis Oocytes", 55:847-854, MOL PHARM, 1999
	Cihlar et al., "The Antiviral Nucleotide Analogs Cidofovir and Adefovir Are Novel Substrates for Human and Rat Renal Organic Anion Transporter 1", 56:570-580, MOLECULAR PHARMACOLOGY, 1999 ✓
	Cundy et al., "Effect of Probenecid on the Distribution, Metabolism, and Excretion of Cidofovir in Rabbits", 24(3):315 - 321, The American Society for Pharmacology and Experimental Therapeutics, 1996
	Fisher et al., "Safety of adefovir dipivoxil (ADV) and Incidence of Proximal Renal Tubular Disorder (PRTD) in a Placebo (PLC)-Controlled Trial in Patients (Pt) with Advanced HIV Disease", Abstract 678, 6th Conference on Retroviruses and Opportunistic Infections, Chicago, IL, Jan 31 - Feb 4, 1999
	Hosoyamada et al., "Molecular Cloning and functional Expression of a Multispecific Organic Anion Transporter from Human Kidney", 45(1):F122-F128, AM J PHYSIOL, Jan. 1999
	Kuze et al., "Heterologous Expression and Functional Characterization of a Mouse Renal Organic Anion Transporter in Mammalian Cells", 274(3):1519-1524, J BIOL CHEM, 1999
	Lalezari et al., "Intravenous Cidofovir for Peripheral Cytomegalovirus Retinitis in Patients with AIDS", 126(4):257-263, ANN INT MED, 2/15/97

EXAMINER DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTY DOCKET NO.: 240.1PCD SERIAL NO.: 10/086,816

APPLICANT: Tomas Cihlar

FILING DATE: 2/28/02

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

GROUP ART UNIT:

1632

(37 CFR 1.98(b))

EXAMR'S INITIALS	ARTICLE
	Lopez-Nieto et al., "Molecular Cloning and Characterization of NKT, a Gene Product Related to the Organic Cation Transporter Family that is Almost Exclusively Expressed in the Kidney", 272(10):6471-6478, J BIOL CHEM, March 7, 1997
	Lu et al., "Cloning of the human kidney PAH transporter: narrow substrate specificity and regulation by protein kinase C", 45(2):F295-F303, AM J PHYSIOL, Feb. 1999
	Lu et al., "Cloning of a Human Kidney P-aminohippurate (PAH) Transporter: Narrow Substrate Specificity and Regulation by Protein Kinase C", 9:54A XP002097951, Journal of the American Society of Nephrology, Sept. 9, 1998
	Mulato et al., "Nonsteroidal Anti-Inflammatory Drugs Efficiently Reduce the Transport and Cytotoxicity of Adefovir Mediated by the Human Renal Organic Anion Transporter 1", 295(1):10-15, The Journal of Pharmacology and Experimental Therapeutics, 3/14/2000
	Race et al., "Molecular Cloning and Characterization of Two Novel Human Renal Organic Anion Transporters (hOAT1 and hOAT3)", 255:508-514, BIOCHEM BIOPHYS RES COMM, 1999 V
	Reid et al., "Cloning of a Human Renal p-Aminohippurate Transporter, hROAT1", 21:233-237, Kidney & Blood Pressure Research, 1998
	Rudinger, J., "Peptide Hormones", pp. 1-7, University Park Press, Baltimore, (J. A. Parsons, ed.), 1976
	Saito et al., "Cloning and Functional Characterization of a Novel Rat Organic Anion Transporter Mediating Basolateral Uptake of Methotrexate in the Kidney", 271(34):20719-20725, J BIOL CHEM, August 23, 1996
	Sekine et al., "Expression Cloning and Characterization of a Novel Multispecific Organic Anion Transporter", 272(30):18526-18529, J BIOL CHEM, July 25, 1997
	Sweet et al., "Expression Cloning and Characterization of ROAT1", 272(48):30088-30095, J BIOL CHEM, Nov. 28, 1997
	Tune, B.M., "Nephrotoxicity of beta-lactam antibiotics: mechanisms and strategies for prevention", 11:768-772, Pediatr. Nephrol., 1997
	Wolff et al., "Expression Cloning and Characterization of a Renal Organic Anion Transporter from Winter Flounder", 417(3):287-291, FEBS, 1997

EXAMINER

DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Section 3. Copi s of List d Information Items Accompanying This Statement

Legible copies of all items listed in Form PTO-1449 accompany this information statement.

Reg. No. 35,071

Tel. No.: (650) 522-5569

SIGNATURE OF ATTORNEY

Mark L. Bosse

Type or print name of attorney Gilead Sciences, Inc.

333 Lakeside Drive P.O. Address

Foster City, CA 94404